Quantcast
Home > Quotes > ALT

Altimmune, Inc. Common Stock (ALT) Quote & Summary Data

ALT 
$2.37
*  
0.09
3.66%
Get ALT Alerts
*Delayed - data as of Jun. 18, 2019 13:27 ET  -  Find a broker to begin trading ALT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ALT Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.37 / $ 2.38
Today's High / Low
$ 2.58 / $ 2.37
Share Volume
212,945
50 Day Avg. Daily Volume
397,708
Previous Close
$ 2.46
52 Week High / Low
$ 36.25 / $ 1.70
Market Cap
31,878,112
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
212,945
50 Day Avg. Daily Volume:
397,708

Trading Range

The current last sale of $2.37 is 39.41% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.58 $ 36.25
 Low: $ 2.37 $ 1.70

Company Description (as filed with the SEC)

Altimmune, Inc. is a clinical stage immunotherapeutics company focused on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. Our product candidates are focused in two key areas for which we have unique proprietary approaches; i) our synthetic peptide technology for cancer and infectious disease, and ii) intranasal vaccines for infectious disease. Using these technologies, we have generated preclinical and clinical product candidates that potentially represent an entirely new approach to harnessing the immune system. In addition, we are seeking to acquire or in-license product candidates in immunotherapeutic indications that are either synergistic or complementary to our capabilities to expand our pipeline. HepTcell HepTcell is an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus ("HBV").  ... More ...  



Risk Grade

Where does ALT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.50
Open Date:
Jun. 18, 2019
Close Price:
$ 2.46
Close Date:
Jun. 17, 2019


Consensus Recommendation

Analyst Info